Related Experiment Video
Updated: Jul 2, 2026
20:23
A Lectin HPLC Method to Enrich Selectively-glycosylated Peptides from Complex Biological Samples
Published on: October 1, 2009
Lectinomics II. A highway to biomedical/clinical diagnostics
Peter Gemeiner1, Danica Mislovicová, Ján Tkác
1Department of Glycobiotechnology, Center for Glycomics, Institute of Chemistry, Slovak Academy of Sciences, SK-845 38 Bratislava, Slovakia.
Biotechnology Advances
|August 16, 2008
Summary
Lectin biorecognition technology is transitioning from low-throughput to high-throughput microarray techniques. Future advancements predict cost-effective lectin microarrays for deciphering cellular glycocode complexity.
Area of Science:
- Biotechnology
- Glycomics
- Biosensing
Background:
- Lectin biorecognition technology is crucial for understanding cellular processes.
- Current methods face limitations in throughput and complexity analysis.
- The glycocode significantly influences cell physiology.
Purpose of the Study:
- To review the current status of lectin biorecognition technology.
- To forecast future trends in lectin microarray development.
- To compare lectins with anti-carbohydrate antibodies for diagnostic applications.
Main Methods:
- Scientometric analysis to characterize technological trends.
- Review of existing and emerging lectin-based techniques.
- Molecular basis analysis of glycan recognition.
Main Results:
- A shift from low-throughput to high-throughput lectin microarray techniques is observed.
- Lectin microarrays show promise in analyzing complex glycan structures.
- Recombinant and artificial lectins are expected to improve microarray cost-effectiveness and flexibility.
Conclusions:
- Lectin biorecognition technology is advancing rapidly, particularly with microarray platforms.
- Further development will enhance the utility of lectin microarrays in glycobiology and diagnostics.
- Mass spectrometry will be vital for characterizing new lectins and their binding profiles.
Related Concept Videos
01:33Enzyme-Linked Immunosorbent Assay
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or quantified.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or quantified.
01:19MALDI-TOF Mass Spectrometry
Mass spectrometry is a powerful characterization technique that can identify and separate a wide variety of compounds ranging from chemical to biological entities, based on their mass-to-charge ratio (m/z). The instruments that allow this detection, known as mass spectrometers, have three components: an ion source, a mass analyzer, and a detector. These spectrometers differ based on the nature of their ion source and analyzers.Matrix-assisted laser desorption ionization (MALDI) is a commonly...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...